Exacerbation of Pre-existing Neurological Symptoms With COVID-19 in Patients With Chronic Neurological Diseases: An Updated Systematic Review

Md Sakibuzzaman 1, Anid Hassan 2, Samira Hayee 3, Fariha Asha Haque 4, Sumaita Sadida Bushra 5, Maisha Maliha 6, Maksuda Khan Tania 1, Anahita Sadat 6, Fahima Akter 3, Tanusree Mazumder 8, Joyeta Razzaque 1, Progga Kapuria 2, Ishra Jalal 5, Prince Shah-Riar 10

1. Department of Neurology, University of Toledo, Toledo, USA. 2. Department of Internal Medicine, Holy Family Red Crescent Medical College Hospital, Dhaka, BGD. 3. Department of Internal Medicine, Chittagong Medical College and Hospital, Chittagong, BGD. 4. Department of Internal Medicine, Jawaharlal Nehru Medical College (JNMC) and Acharya Vinoba Bhave Rural (AVBR) Hospital, Wardha, IND. 5. Department of Internal Medicine, Jahurul Islam Medical College and Hospital, Kishoreganj, BGD. 6. Department of Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD. 7. Department of Internal Medicine, Ibrahim Medical College and Birdem General Hospital, Dhaka, BGD. 8. Department of Internal Medicine, Zainul Haque Sikder Women’s Medical College and Hospital, Dhaka, BGD. 9. Department of Internal Medicine, Khulna Medical College and Hospital, Khulna, BGD. 10. Department of Gastroenterology, Ibn Sina Medical College, Dhaka, BGD

Corresponding author: Samira Hayee, samira.jamias0610@gmail.com

Abstract

The neurotropism of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can potentially explain the worsening of symptoms in patients with a history of neurological conditions such as stroke, Parkinson’s disease, Alzheimer’s, and epilepsy. Several studies have reported that these pre-existing conditions may worsen with a higher frequency of flare-ups, thus resulting in a more significant risk of patient mortality. In this review, we sought to provide an overview of the relationship between pre-existing neurological disorders and COVID-19, focusing on whether the initial infection directly influenced the severity of symptoms. We systematically searched the electronic database PubMed (MEDLINE) and used specific keywords related to our aims from January 2020 to July 2022. All articles published on COVID-19 with keywords pertaining to pre-existing neurological diseases were retrieved and subsequently analyzed. After independent review, the data from 107 articles were selected and evaluated. After analyzing the data from selected articles reviewing the effect of COVID-19 on neurological conditions, we have documented the relationship between said pre-existing neurological diseases, showing an increased risk of hospitalization, admission length, worsening of symptoms, and even mortality in COVID-19 patients.

Introduction And Background

The 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic caused a profound impact, infecting three million lives and causing a death toll of almost 600,000 people alone in the United States. The crisis led to enormous patient overload in health care facilities worldwide, with symptoms often leading to profound multiorgan failure and high mortality rates. One of the systems the SARS-CoV-2 frequently infiltrated was its access within the central nervous system (CNS), and the neurotropism of COVID-19 can explain the exacerbation of neurological symptoms in patients with a history of stroke, Parkinson’s disease (PD), Alzheimer’s disease, multiple sclerosis, and epilepsy [1].

The high viral spread of the SARS-CoV-2 raised successive sequela of long-term concerns particular to those with underlying severe neuro-medical illnesses, leaving patients with severe additional impairments to their functional disabilities [2]. These CNS complications are caused via the SARS-CoV-2’s inflammatory responses within the immune system, with additional consequences resulting in patients with symptoms of ischemic or hemorrhagic stroke having a higher risk of mortality than other hospitalized patients [3]. Patients exhibiting pre-existing brain pathologies - such as dementia and Alzheimer’s - experienced exacerbating symptoms that caused the further cognitive functional decline. Those with PD and multiple sclerosis also experienced heightened mobility issues when exposed to SARS-CoV-2 [4]. In addition to the emotional and social isolation resulting from the pandemic, most patients affected by pre-existing degenerative motor disorders were unable to get proper in-person evaluations and thus had a greater risk of their comorbid conditions developing into severe pneumonia and being admitted to critical care [5]. Patients with uncontrolled epilepsy were also more likely to experience more significant health impacts from COVID-19, as medically induced sedation and ventilations would present a risk of emerging seizures during treatment and would be difficult to suppress due to epilepsy or severe immune dysfunction being refractory.

doi:10.7759/cureus.29297
to possible medications [6]. Therefore, the current study aimed to search whether the patients with pre-existing neurological disorders had a significant exacerbation of their symptoms and whether their severity was due to the initial infection.

**Review**

**Methodology**

Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7], a systematic review was conducted based on the articles published from January 1, 2020 to July 31, 2022. This review was not officially registered. For data collection, we performed a comprehensive search strategy online using MEDLINE (accessed from Pubmed.) We searched the database using search terms including but not limited to “pre-existing neurological disorders and COVID-19,” “exacerbation of neurological disorders,” “new neurological symptoms,” “COVID-19,” “Corona Virus and Neurological disorders,” “Parkinson’s Disease,” “Stroke,” “Multiple Sclerosis,” “Alzheimer’s Disease,” “Epilepsy” “Dementia,” “pre-existing and nervous system disease,” “Neurological disorders and COVID.”

We included the studies that met the following criteria: 1) All the studies have PICO (Patient or problem, Intervention or exposure, Comparison or control) framework, 2) Original articles such as systematic reviews and meta-analyses, cross-sectional studies, case-control studies, longitudinal studies, case reports, case series were included, 3) aged over 18 years, 4) patients diagnosed with COVID-19 according to World Health Organization (WHO) standards reporting exacerbation of pre-existing neurological diseases or newly developed neurological symptoms and 5) Articles reporting patients with pre-existing neurological diseases and COVID-19. We excluded pediatric cases (age<18 years), studies written in foreign languages, non-neurological disorders, neuropsychiatric disorders like schizophrenia, mood disorders, pre-clinical trials, studies on vaccine or drug effects, and studies with different outcomes from the final review.

The severity of COVID-19 was defined as any patient who needed admission to the hospital or Intensive Care Unit (ICU) with severe respiratory distress, low oxygen saturation, or any other critical complications. A total of 1,273 articles were retrieved relevant to our initial keywords from the online database. Eight independent reviewers then screened the titles and abstracts and excluded the duplicate 1,118 non-relevant studies. In the end, a full-text screening of the remaining 162 studies was completed to check for eligibility. Subsequently, the studies were subcategorized according to the aforementioned neurological conditions. Additional four reviewers resolved any controversies during the screening steps.

Finally, a total of (N=107) studies were selected as eligible for review (Figure 1). All the articles went through extensive deliberations, scanning the relevant information and paraphrasing the essential points for analysis in google spreadsheets for four months. Any discrepancies were solved among the authors by thorough discussion.
Our systematic review had some limitations. Firstly, the studies were searched only in PubMed. However, we limited it to PubMed to ensure good quality and avoid predatory articles. Furthermore, some confounders may have influenced the correlation between COVID-19 and worsening neurological disease symptoms. Finally, there might be some nonuniformity between the included research articles. For example, study size, neurological complications, study designs, and data collection varied among the included studies; hence, the findings must be interpreted cautiously (Tables 1, 2).
**Name of disease** | **New symptoms after COVID-19** | **Hospitalization due to COVID-19** | **COVID-19 related mortality**
---|---|---|---
**Stroke** | Anosmia, fatigue, dizziness, headache, and myalgia; Dizziness, Headache, Confusion, Altered mental status, Facial droop, Slurred speech, weakness, and Paralysis; Difficulties in memory, poor concentration, visual disturbance, decreased consciousness levels, seizures, delirium, involuntary movements, and ataxia | Duration of hospital stay was generally increased. | COVID-19 patients with stroke had higher chances of worse outcomes and more significant mortality than those without.
**Parkinson's disease (PD)** | Exaggeration of motor symptoms was more common than non-motor symptoms | Increased hospitalization and ICU admission rate among known Parkinson’s patients | Higher mortality rate compared to patients with no neurologic disorders
**Delirium** | Not related to developing new symptoms. | Patients previously diagnosed with dementia are more likely to develop delirium and less likely to exhibit some other COVID-19 symptoms on presentation. | Delirium associated with COVID-19 has been associated with increased mortality.
**Alzheimer's disease (AD)** | Neuro-degeneration, Cognitive decline memory deterioration, behavioral changes, orientation abilities, reduced levels of independence, functional decline, and new or deteriorating behavioral disturbances, including aggression, apathy, and depression | People with Alzheimer's Disease are at high risk of contracting COVID-19 and develop worsening outcome | Increased risk of mortality
**Multiple sclerosis (MS)** | Multiple Sclerosis exacerbation or recrudescence or additional signs not typical of MS | Increased in Progressive MS subtype or presence of other comorbidities | Not increased
**Epilepsy** | Headache, Myalgia, Delirium, Parageusia, Anosmia, Limb weakness, Distorted mental status after withdrawal of sedatives, | Not increased | Increased risk of mortality and sudden unexpected death.

**TABLE 1: Neurological symptoms and severity in patients with pre-existing chronic neurological diseases**

| Author (Reference) | Study Design | Age (mean ± SD) | Male (%) | Total Number of patients with neurological disorders | Types of neurological disorder | Key exacerbating symptoms or severe symptoms | Number of patients with pre-existing neurological disorders having severe COVID symptoms | Death or Mortality rate (%) |
|---|---|---|---|---|---|---|---|---|
| Asadi-Pooya et al. [8] | Case control study | 53±23 | 53.2 | 1086 | Epilepsy, Cerebrovascular accident, Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Unspecified | Seizure | NA | Case fatality rate 8.5% |
| Brown et al. [9] | Cross sectional study | 63±73 | 73% | 5429 | Parkinson’s disease | Motor and Non-motor symptoms (mood, cognition, sleep, autonomic) | NA | NA |
| Drabik et al. [10] | Cohort study | 64±45.28 | 349 | Stroke, Dementia, Parkinson’s disease, Epilepsy, CNS tumor, Traumatic brain injury | Headache, Dizziness, dementia, decreased consciousness, stroke, seizure, ataxia | NA | 9.46 |
| El-Quraey et al. [11] | Systematic review and meta-analysis | NA | NA | 8649 | Parkinson’s disease | NA | Poor in-hospital outcomes of COVID-19 (OR 2.04 [95% CI 1.75-2.36], p < 0.00001) | 25.10% |

4 of 16

2022 Sakibuzzaman et al. Cureus 14(9): e29297. DOI 10.7759/cureus.29297
| Authors                  | Study Type           | Control Study | Design Study | Neurological Disorders                                                                 | COVID-19 Complexes                  | Other Conditions                                                                 | Mortality Increase |
|-------------------------|----------------------|---------------|--------------|----------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------|-------------------|
| Eskandar et al. [12]    | Control study        | 65            | NA           | Stroke, Seizure                                                                         | Allergic manifestation, Stroke, Seizure, Neuro covid 19 complexes | NA                                                                 | 58.70%            |
| Fan et al. [13]         | Cross-sectional study| NA            | NA           | Multiple Sclerosis, Neuromyelitis Optica Spectrum disorders                              | Stroke, Seizure, Delirium, Mynypathy, Headache | NA                                                                 | 2                 |
| Flores-Silva et al. [14]| Cross-sectional study| 53.2 ± 15.7   | 65           | Epilepsy, Ischemic stroke, Multiple sclerosis, and Parkinson’s disease                  | Seizure, Stroke, Delirium, Mynypathy, Headache | NA                                                                 | 19.60%            |
| Geppetti et al. [15]    | Prospective cohort study | 49 (<4aka) | 50 (≥4aka) | 79/77 Multiple sclerosis                                                                | Change in smell or taste, headache, fever, New muscle pain, and New or worse fatigue, Upper respiratory tract, lower respiratory tract and Gastrointestinal tract symptoms | 1096               | NA                 |
| Harb et al. [16]        | Cohort study         | 84 (for patients with dementia) | 43.1 | 116 | Dementia | Delirium, Dyspnea | 50/116 (developed ARDS) | 50 |
| Hu et al. [17]          | Cohort study         | 74.2 ± 5.84   | 53           | Neurodegenerative disease                                                               | NA                                  | 379                                                               | 7.5               |
| Huber et al. [18]       | Prospective cohort study | Median decade | 59          | Parkinson’s disease, Dementia                                                          | Dry cough, Dyspnea, Fever, Delirium, Headache, Taste disorder | NA                                                                 | 32.5 (Parkinson’s disease) |
| Kuroda et al. [20]      | Review article       | NA            | NA           | Epilepsy                                                                                | Seizure                             | NA                                                                | NA                |
| Louapre et al. [21]     | Cohort study         | 44.6±12.6     | 28.2         | Multiple sclerosis                                                                      | ARDS                               | 73                                                                | 3.46              |
| Nejed et al. [22]       | Cross-sectional study | Different age group was compared | 57.2 | 891 | Stroke, Seizure | Headache, sleeping problem, anosmia, dizziness, hypoguesa, memory issues, seizure | NA | NA |
| Numbers and Brodaty [23]| Review article       | NA            | NA           | Alzheimer’s disease                                                                     | Severe virus related outcome including death | NA | Mortality increased |
| Parrotta et al. [24]    | Cross-sectional study | 44.9 ± 15.2   | 38.2         | Multiple sclerosis                                                                      | Relapsing of neurological symptoms    | 8                                                                | 8.33              |
| Santos-Garcia et al. [25]| Cross-sectional study | 63.5±12.5 | 47 | NA | Parkinson’s disease                                                                   | Tremor, rigidity, fluctuation of motor symptoms, etc. | NA | NA |
| Yassin et al. [26]      | Systematic review and meta analysis | 50.3 | 53 | NA |                     | Myalgia, taste impairment, small impairment, headache, dizziness, encapsalopathy, CVD. | NA | NA |
| Zhang et al. [27]       | Case series          | 70 (for stroke patients) | 49 | Stroke                     | Sepsis, ARDS, Acute kidney injury | NA | 45 |

**TABLE 2:** Summary of patients with neurological disorders and COVID-19
**Discussion**

**Neurotropism of COVID-19 and Its Role in Patients With Pre-Existing Neurological Conditions**

As a consequence of COVID-19, several cases presented with various neurological complications [28]. These patients have a worse neurological outcome than the general population's neurological symptom exacerbation. Therefore, our study evaluates the exacerbation of neurological manifestations and the intensity of COVID-19 in patients with pre-existing neurological disorders (Figure 2) [29].

**FIGURE 2: Mechanism of aggravation of neurological manifestations due to COVID-19**

This figure is a self-illustration by the authors.

**Pathophysiology of COVID-19-Related Stroke**

Three main mechanisms responsible for ischemic strokes in COVID-19 include a hypercoagulable state, vasculitis, and cytokine storm [30].

**Hypercoagulable state:** Significantly higher average levels of D-dimer, CRP as well as decreased fibrinogen levels were found in COVID-19 patients who had cerebrovascular manifestations reported by Li et al. [31], indicating hypercoagulable states resulting from inflammation and leading to stroke [32]. Based on this hypercoagulability, significant vessel stenosis was found in five of 11 patients (45.5%) in a study by Li et al. [31]. Large vessel occlusion and hemorrhagic transformation of an ischemic stroke with COVID-19 or more susceptible to intracerebral hemorrhage (ICH) [33].

Vasculitis and pathogenesis of ischemic stroke due to ACE-2 receptors: According to Varga et al., the vascular endothelium is rich in ACE-2 receptor that, when exposed to the COVID-19 virus, causes an inflammatory response (a lymphocytic "endotheliitis") that both creates a surplus of immune cells and acts as one of the substrates for the thrombotic complications [34].

While the exact theory of how hemorrhagic stroke with COVID-19 infection occurs is still uncertain, some idea of the ACE-2 receptors on the brain endothelial and arterial smooth muscle cells allows the vulnerability and damage by the virus, enabling the vessel to be more prone to rupture [35]. Few case reports mentioned that the pathogenesis could be a multifactorial combination of small vessel vasculitis, microvascular thrombosis, dysfunction of the endothelial lining, or even imbalance of the RAAS system causing the risk for stroke [56]. The SARS-CoV-2 spike protein surface unit interacts by entering the cell membrane-bound protein with the aid of an angiotensin-converting enzyme (ACE-2) receptor, which is known to have the effects of causing vasodilation via its antihypertensive, antifibrotic and antiproliferative effects. This dysregulation, especially in endothelial cells, can lead to the inhibition of fibrinolysis and further thrombin production [37].
COVID-19 severely affected ICU patients who needed ECMO and were treated with higher doses of anticoagulants which could be a reason for getting more hemorrhagic stroke than ischemic stroke as a complication [38]. Pathogenesis may be related to SARS-CoV-2 with an affinity for ACE-2 receptors, allowing the virus to damage intracranial arteries causing vessel walls to rupture and cause hemorrhage [35]. Cytokine storms could also cause hemorrhagic strokes, as reported in a diagnosed COVID-19 patient who developed an acute necrotizing encephalopathy associated with late parenchymal brain hemorrhages [39].

Pathophysiology with interferons and cytokine storms: Analytics found IL-2, IL-6, tumor necrosis factor (TNF), and anti-phospholipid antibodies were profoundly activated by the human immune system, which then triggered the massive response to the "cytokine storm," which degraded the extracellular matrix (ECM), the lining of the endothelial lumen. Plaques from ECM degradation and blood components of substances were the triggering factors for blood to be hypercoagulable and stagnant, a risk especially for ischemic and some hemorrhagic strokes [40]. However, IL-6 may also help increase post-stroke angiogenesis and provide protection in ischemic stroke [41]. Patients can have confusion and altered states of consciousness due to proinflammatory cytokines that increase markers hypercoagulation increasing the risk of stroke. Dodd et al.'s study analyzed the inflammatory response triggered by COVID-19 infection could be the factor to cause saccular premature aneurysms to rupture and subarachnoid hemorrhage [42].

Pathophysiology of PD and COVID-19: According to Brown et al. [9], 18% with PD also reported new motor symptoms and worsening previous symptoms during the pandemic. The possible mechanisms for aggravating symptoms are a systemic inflammatory response to the SARS-CoV-2 virus [43], social isolation [44], discontinuation or miss in medication doses, lack of exercise, social activities, and missing follow-up visits [45].

Pathophysiology of multiple sclerosis and COVID-19: Clinical relapse of MS is precipitated by auto-activation of peripheral T and B lymphocytes and resident CNS immune cells, which enter the CNS by crossing the blood-brain barrier and aggravating the demyelination of neurons [53]. Depletion of the antiviral CD8 response [54] results from the fact that in about 80% of COVID-19 patients, CD3 +ve, CD8 +ve, and CD4 +ve T cell counts are typically decreased, and recovery of the normal count of T lymphocytes takes place in between 2 and 12 months [55]. This may promote infection by latent microbes with the ability to trigger Multiple Sclerosis [56]. Additionally, alterations in intestinal pathogens and intestinal barrier breakdown can be detected as neuroinflammatory mediators by the gut-brain axis and may exacerbate MS by intensifying autoimmune responses. Fluctuations in the body or ambient temperature and febrile illnesses like COVID-19 can worsen neurological symptoms [57].

Pathophysiology of epilepsy and COVID-19: A proposed hypothesis is that the COVID-19 virus can enter the CNS via axonal transport, blood-brain barrier, or olfactory bulb [58]. Another exciting theory is that distress imposed by social isolation may lead to breakthrough seizures and aggravated neurological symptoms in patients with preexisting epilepsy. In addition, hypoxemia, drug-drug interactions, and metabolic abnormalities may also contribute to worsening neurological episodes in COVID-19 patients with epilepsy [9].

Neurological and non-neurological symptoms of COVID-19

Stroke

COVID-19 most commonly presents with fever, cough, sore throat, nausea, vomiting, anorexia, fatigue, and in severe cases, sepsis and pneumonia. SARS-CoV-2 has the propensity to affect both CNS and PNS. In the first 14 days in patients infected with SARS-CoV-2 infection, involvement of the peripheral and central nervous systems is well known [59]. Neurological symptoms during SARS-CoV-2 range from mild clinical features like anoxia, fatigue, dizziness, headache, and myalgia to severe clinical presentations like encephalopathy and ischemic strokes, hemorrhagic, and rare times aneurysms [60]. Difficulties in memory, poor concentration, visual disturbance, decreased consciousness levels, seizures, delirium, involuntary movements, and ataxia are also known [10]. About 20% of patients admitted to the ICU for COVID-19 reported neurological manifestations and complications, and those with neurological issues predating their COVID-19 diagnosis presented a higher mortality rate.
Stroke as the First Symptom of COVID-19

Several studies have contributed to our evolving understanding of the association between stroke and SARS-CoV-2 infection. In some cases, stroke was the presenting symptom for patients testing positive for COVID-19. In a multicenter study by Trifan et al. based in Chicago, 83 patients were included based on radiological evidence of stroke and positive COVID-19 diagnosis. Among them, 32 patients (39%) presented with stroke as the primary diagnosis. Ischemic Stroke was found to be the most frequent subtype (77%), intracranial hemorrhage (ICH) (19%) was second, followed by subarachnoid hemorrhage (SAH) (4%) [61]. The authors also sought to describe the association of stroke with COVID-19 in demographic distribution; for example, 53% were males among 83 patients included in the study. 75% were Hispanic or Black, and the median age was 64. They concluded that males had higher risks of getting severe COVID-19 infections and suffering from worse ischemic stroke outcomes than females [61]. The chances of a stroke are 7.6 times higher in COVID-19 patients than in patients with historic influenza infection. The young individuals with positive COVID-19 disorder who had no prior vascular risk factors got a large vessel stroke which is seven times higher, in contrast, another study demonstrated that irrespective of age, sex, and vascular risk, stroke was independently associated with COVID-19 [62]. Li et al. reported that among 221 patients, 13 (5.9%) patients were found to develop acute cerebrovascular events. Among them, 11 patients developed acute ischemic stroke, cerebral venous sinus thrombosis in one (0.5%), and ICH in one (0.5%) patient, respectively [31].

Symptoms of Stroke and Effects of COVID-19 on Pre-existing Stroke

Avala et al. elucidated that about four patients admitted in a medical emergency with acute stroke-like symptoms such as altered mental status, facial droop, slurred speech, left-sided weakness, right arm weakness, numbness and other symptoms [63]. COVID-19 patients with pre-existing cerebrovascular disease are at increased risk of developing poorer outcomes [64]. This is commonly seen in patients with at least one baseline vascular risk factor (VRF) in which arterial hypertension is the most prevalent. Those with stroke with VRF are likely to have a worse prognosis [65]. In a meta-analysis containing 47 included studies involving 7,267,055 patients, comorbid stroke was associated with an increased risk of mortality in Covid-19 patients (pooled effect = 1.30, 95% CI: 1.16-1.44, random-effects model) based on confounder-adjusted effect estimates [66]. Previous studies also suggest that patients with pre-existing cerebrovascular diseases might be prone to increased stroke risk with COVID-19 [53]. Even among non-infected patients, indirect consequences of the COVID-19 pandemic could increase stroke morbidity and mortality. Hypercoagulability and thromboembolism result from the robust inflammatory response caused by COVID-19 [67].

Extracorporeal Membrane Oxygenation (ECMO)

Although stroke has etiological causes like hypertension, atherosclerotic plaque formation, and dislodgement of emboli due to atrial fibrillation, other etiological factors also contributing to COVID-19 treatments causing a stroke is the use of ECMO or also known as extracorporeal life support. The importance of this technique is to prolong the consent to the cardio-respiratory system in those with an inadequate amount of gas exchange and lack of sustained perfusion due to circulatory collapse. Patients with severe states of COVID-19 with compromised pulmonary conditions due to terminal stages of pneumonia and low oxygenation, which failed to improve with oxygenation masks, started to show neurological instability and cardiac failure. These critical patients were then placed on ECMO to help strengthen their oxygenation. However, these patients on ECMO were unfortunately at risk of air embolism complications, which increased the risk of ischemic stroke and rarely intracranial hemorrhage due to embolism lodgement [68]. Patients on either veno-arterial (15%-18%) or venovenous (4%-13%) ECMO were at risk of neurological complications [69]. Based on a recent study by Cho et al., it is discovered that comparing the patient’s status of those before being admitted into ICU without ECMO, the higher chance of occurrence of ischemic or hemorrhagic stroke occurred to those in ECMO during their ICU [38].

Robinson et al.’s study of 2,699 COVID-19–positive patients, the median age of 59, 65% male, 70% of patients were on mechanical ventilation, and 10.5% on ECMO. Of this cohort, 75 patients had strokes as a complication of hospital stay, and 16 were excluded for unknown stroke timing occurrence during their time of admission. Of these 59 patients studied out of the cohort, 27 (46%) patients had a hemorrhagic stroke, 19 (32%) patients had an ischemic stroke, and 13 (22%) patients were unspecified on their type of stroke based on the Imaging (CT or MRI) [70]. Hence, ECMO is shown to have a higher risk of hemorrhagic stroke than ischemic type. Robinson et al. compared ECMO patients developing stroke against those without ECMO developing stroke. In 283 patients with ECMO, 15 (5.3%) had a hemorrhagic stroke, three (1.1%) patients had an ischemic stroke, and four (1.4%) were unspecified strokes. Of these 283 patients, 94% (266) of the people had venovenous ECMO, and the remaining venoarterial ECMO supported 17 patients [70]. Those with stroke while being treated with ECMO were more critical patients with more frequent needs for mechanical ventilation and vasopressor treatment support. In the non-ECMO group, among 2,415 patients, 12 patients (0.4%) had a hemorrhagic stroke, 16 patients (0.6%) had an ischemic stroke, and nine patients (0.3%) were defined as having an unspecified type of stroke [70].

Hemorrhagic Stroke
Most patients from the general population who develop COVID-19-related stroke are commonly ischemic, although there have been a few hemorrhagic cases [71]. Trifan et al. [61] found the incidence of ICH to be 19% among his cohort of cases, 38% of which were discovered during hospitalization. The median Glasgow Coma Scale/Score (GSC) was 14, and the ICH score was 2 in clinically symptomatic patients (88%). ICH was to be most commonly caused spontaneously (44%) or was related to anticoagulation (44%) [61]. The mortality rate among the ICH patients with COVID-19 was 50%, with the modified Rankin Scale (MRS) of those who survived being 2 [61]. During hospitalization, many patients were placed on anticoagulation which increased the bleeding risk, particularly the cases of intracranial hemorrhage. Patients with oral anticoagulation had a higher mortality rate than those with a spontaneous cause of ICH [72].

Doga et al. study that anticoagulation increases the risk of ICH [73]. In his study cohort of 3,824 COVID-19 positive patients, 33 patients were reported to have a hemorrhagic stroke: five (15.2%) patients with parenchymal hemorrhage resulting in herniation from mass effect with radiological imaging of diffuse hypoxic injury and mortality rate of 100% [73]; Females (21.2%); mean age of 61.6 years (range of 37-83 years) and mortality of 14 (42.4%) patients; 15 (45.5%) continued hospitalization and four (12.1%) patients discharged. Those with a high D-dimer were initiated with anticoagulants based on their hypercoagulability state. 2,204ng/mL was the median D-dimer before the hemorrhage was diagnosed. Anticoagulants used in the cohort were intravenous heparin, argatroban, or enoxaparin, of which 40mg was used subcutaneously daily or twice for those with BMI<40 and 30mg twice daily for BMI<40 [74]. Doga et al.’s study of the remaining 28 (25%) patients who presented with punctate hemorrhage of the cortex, small hemorrhages were seen in 17 (60.7%) patients, and large single hemorrhages were found in four (14.3%) patients. Mortality was seen in eight (53.3%) patients with small and punctate hemorrhages and one (25%) in those with a single large hemorrhage without herniation [73].

Diagnostics Assessments and Predictors of Neurologic Manifestations for Stroke

For all patients suspected to present with stroke symptoms, apart from looking into their comorbidities and risk factors placing patients at higher mortality risk, the SARS-CoV-2 virus further exacerbated stroke to be the most prominent neurological adverse effect in those with positive COVID-19 infection. Evaluation of diagnosing parameters for stroke is the same in patients with or without COVID-19. Initiation of hypercoagulability testing profiles of activated partial prothrombin time (aPPT), prothrombin time (PT), d-dimer, and fibrinogen with complete blood count (CBC) to rule out hematologic aspects in mind. This is evaluated at the time the patient’s stroke lasts if <4.5hrs or >4.5hrs with the use of neurovascular and brain imaging to look for venous or arterial causes of cardiovascular reasons and whether the stroke is ischemic or hemorrhagic [73]. COVID-19 in few studies has shown that, unlike other viral infections, it can increase the chance of having an ischemic stroke to 7.6% with very high levels of D-dimers, which reflects the high clotting turnover and being an aggressive thrombotic, further increasing the chances of ischemic stroke. Furthermore, COVID-19 patients from the underlying hypercoagulable may also be at higher risk for a reoclusion after thrombectomy done mechanically [76].

Eskandar et al. highlight the predators of patients presenting with neurological findings [12]. They found that patients who have a prior stroke history had comorbidities of renal disease (blood urea nitrogen >30 mg/dL, creatinine >1.5 µmol/L), heart failure, and chronic obstructive pulmonary disease (COPD) of black race or Latino ethnicity were more at risk. Looking at the parameters, he demonstrated those with hypercoagulability states of d-dimers >5 mg/L, <150,000/mm³ platelets, >1.2 international normalization ratio (INR) and >0.1 ng/mL procalcitonin and troponin >0.1 ng/ml were at higher risk as potential correlation to neurologic presentations [12].

Stroke Imaging Findings in COVID-19 Patients

Physical signs of stroke within patients, such as muscle paralysis and facial drooping, shortly after being infected with the SARS-CoV-2 may be considered surrogate markers of a systemic neurological disorder affecting the circulatory system. Diagnosis and confirmation of stroke are usually made with computed tomography (CT), and findings within the neuroimaging often consist of either acute infarction or hemorrhage. Ladopoulos et al. conducted a review of neurological disorders and their alternate manifestations of ischemic and hemorrhagic stroke within neuroimaging; summarizing that within COVID-19 patients, large vessel occlusion (LVO) was the most common observation in the total acute ischemic stroke (21.6%-72.5%), followed by multiple LVOs (14.9%) and lacunar strokes (7.5%-8.7%) with occasional hemorrhagic transformations of ischemic strokes [61]. The most common types of intracranial hemorrhage (ICH) include subarachnoid and intraparenchymal ICH of non-hypertensive locations of lobar, cortical, and junctions of cortico-subcortical areas. He also highlighted that critically ill COVID-19 patients on mechanical ventilation were prone to having multiple cerebral microbleeds (MCB) found in juxta cortical white matter. Trifan et al. showed the characteristics and neuroimaging evidence of acute ischemic stroke among 77% of patients whose most common infarct location was cortical. However, a quarter of patients had a bilateral hemispheric presentation [77]. Stroke of undetermined etiology (39%) was the most common, followed by cardio-embolism (27%). Treatment with tPA was done in 8%, and endovascular thrombectomy was done in 11%. The mortality rate among ischemic stroke patients with COVID-19 was 27%, and the modified Rankin Scale (MRS) at discharge was 4.
Managing treatment during the pandemic was challenging due to the virus’s high morbidity and relative recency of emergence. Joint stroke management includes the use of anticoagulants, anti-inflammatory, and thrombolytics; however, with more knowledge of the SARS-CoV-2 affinity for ACE-2 receptors within endothelial lumens, the use of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors was started as a trial to help stabilize patients’ symptoms [56]. Tang et al. reported that COVID-19 patients with coagulopathy could reduce mortality with anticoagulation treatment such as direct oral anticoagulants (DOAC), heparin, or warfarin [78]. According to Asakura and Ogawa, COVID-19-associated coagulopathy presents some features that may suggest disseminated intravascular coagulation (DIC) and recommended a combination of heparin and Nafamostat mesylate [79]. Anti-inflammatory therapeutics such as IL-6R monoclonal antibodies (tocilizumab), TNF-α inhibitors (etanercept and infliximab), and IL-1β antagonists (the monoclonal antibody canakinumab and the anti-cytokine anakinra) could potentially serve as effective COVID-19 management, based on their benefits in cardiovascular clinical trials [80]. However, immunosuppression, including corticosteroids, may hamper the elimination of the virus, and those with an impaired immune system have more risk of developing secondary infections [81]. As for antiviral therapy, Beigel et al. reported that in a randomized controlled trial in 1,062 patients hospitalized for COVID-19, Remdesivir was associated with a shorter recovery time compared with placebo (10 days in comparison to 15 days, 95% CI: 9-11 to 13-18), and lower 14-day mortality of 6.7% with Remdesivir versus the placebo’s 11.9% (hazard ratio for death, 0.73; 95% CI: 0.52-1.03) [82].

COVID-19 patients with stroke had higher chances of worse outcomes and more significant mortality than those without [83]. Patients with a history of CNS involvement had the worst prognosis. Due to the pandemic, utilization and access to healthcare were interrupted, which may have deterred stroke patients from seeking appropriate care, falsely affecting data. The mortality rate was seen to be high in most COVID-19 patients after stroke manifestations, with further highlighting factors of elevated d-dimers reflecting a hypercoagulable state from the effects of the viral infection’s impact on the endothelial cell.

**Parkinson’s Disease**

PD is a neurodegenerative disorder commonly presenting with motor and non-motor symptoms [84]. Worsening of both motor and non-motor symptoms of PD during COVID-19 infection has been reported in previous literature (Table 2). A systematic review said that 60% of patients with pre-existing Parkinson’s or dementia developed worsening neurological symptoms [19]. Among the reported worsened symptoms, bradykinesia was the most common one. Other motor symptoms were gait disturbances, tremors, and rigidity. Aggravated non-motor symptoms were sleep disturbances, cognition, autonomic, mood disorders like anxiety, depression, appetite disorders, repeated falls, and pain [9]. Some studies also looked at the new diagnosis of Parkinson’s following COVID-19 infection. Li et al. reviewed a temporal relationship between new-onset parkinsonism and COVID-19 disorder. These cases had no obvious motor symptoms or positive family history before getting infected by SARS-CoV-2 [9]. However, we could not exclude the possibility of the early stage of undiagnosed PD [85].

Another intriguing link to consider in PD patients is the severity of COVID-19 symptoms in this population. One systematic review showed the hospitalization rate among PD patients along with COVID-19 was about 40%, and the mortality rate was about 25% [11]. Based on our study, we could say that some of the following factors may play an essential role in developing severe COVID-19 in Parkinson’s patients with increased hospitalization or ICU admission. People with Parkinson’s disease with COVID-19 seem to have an increased risk of pneumonia and clinical deterioration that led to hospitalization [86]. According to Sulzer et al., the commonest cause of hospitalization is a severe infection due to high viral load or pro-inflammatory conditions that increase the need for supported breathing and mechanical ventilation in older PD patients [87]. Another factor to consider is older age and male sex [88]. The average age of PD diagnosis is around 60÷10 years for male patients. Older PD patients tend to present with some atypical symptoms of COVID-19, such as delirium and functional impairment without obvious physical symptoms [88]. Furthermore, complex therapeutic management and limitations in in-patient consultation led to more hospitalization. From all the published reports, we found that the duration of PD is also an essential factor [89]. We can say the more extended the PD duration, the higher the risk for poor outcomes from COVID-19 [90]. Patients with long-term Parkinson’s suffer more severe illnesses requiring hospitalization and ICU admission. Other pre-existing comorbidities in PD patients, such as hypertension, heart disease, and diabetes, seem linked to severe COVID-19 infections [88]. Based on these previous studies, we can say that PD significantly affects the severity and prognosis of COVID-19 conditions.

**Delirium**

Delirium was identified when an electronic medical record (EMR) described the COVID-19-affected patient as being altered or confused. The new confusion is now a CDC emergency warning sign for COVID-19, and the results of this cohort suggest that about one-third of people with dementia present with delirium [16]. Patients who were previously diagnosed with dementia are more likely to develop delirium (36.2% vs. 11.6%, p < 0.001), and a post-doc logistic regression showed that this remains significant after age and gender.
symptoms in the patients (Table 1). Developed worsening neurological symptoms among hospitalized patients with COVID-19 in Mexico City, 15 patients previously who had epilepsy. Epilepsy is a significant component of pre-existing neurological triggers. In a study conducted International Federation, benefit ratio should be measured before stopping treatment, as suggested by The Multiple Sclerosis (DMTs) might increase the chance of developing complications from a COVID-19 infection, too, so the risk-DMT-treated patients had a higher likelihood of contracting SARS-CoV-2 vaccine effectiveness, SARS-CoV-2 antibody levels can be assessed after vaccination or depleted immunity against the virus, as immunotherapy can reduce vaccine response and patients should be educated to remain observant even after vaccination due to the possibility of absent against SARS-CoV-2, irrespective of their immunosuppressive status. Vaccination should not be delayed, and patients should be educated to remain observant even after vaccination due to the possibility of absent or depleted immunity against the virus, as immunotherapy can reduce vaccine response. To determine vaccine effectiveness, SARS-CoV-2 antibody levels can be assessed after vaccination. Additionally, DMT-treated patients had a higher likelihood of contracting SARS-CoV-2. Disease-modifying therapies (DMTs) might increase the chance of developing complications from a COVID-19 infection, too, so the risk-benefit ratio should be measured before stopping treatment, as suggested by The Multiple Sclerosis International Federation. Epilepsy

Epilepsy is a significant component of pre-existing neurological triggers. In a study conducted among hospitalized patients with COVID-19 in Mexico City, 15 patients previously who had epilepsy developed worsening neurological symptoms. Headache and myalgia were the most frequently reported symptoms in the patients (Table 1), standing at 41.7% and 38.5%, respectively. Other common complaints
Cureus were delirium (15.1%), parageusia (8%), anosmia (7%), limb weakness (5.1%), and distorted mental status after withdrawal of sedating medications (2.5%) [14]. This was further strengthened by two studies conducted where the seizure was reported with increased frequency in COVID-19 with a previous history of epilepsy [40,105]. Furthermore, the mortality risk was twice as high in COVID-19 patients with a background of epilepsy [102]. Still, enough data was not found to conclude that it was an independent factor determining mortality. According to some societies, the risk of sudden unexpected death in epilepsy may be increased due to COVID-19. According to some research, sudden unexpected death in epilepsy (SUDEP) may be more likely due to infection or viral disease. However, there is still no evidence that COVID-19 and SUDEP are linked.

Interestingly, COVID-19 itself may lead to the development and worsening of epilepsy [106]. In 2020 in the UK, people mentioned a change in seizures (19%), mental health difficulties (34%), and sleep disruption (26%). A survey has been done on patients with epilepsy (68%) and their caregivers (32%) [107]. Anxiety, depression, social isolation, physical inactivity, and disruptions to social life are all examples of stressors that can increase seizure frequency. Other factors such as decreased adherence to anti-epileptic medication and difficulty in acquiring access to healthcare can contribute to increased epileptic attacks [108]. Statistically significant data were reported in which 15% demonstrated impaired adherence to medication due to changes in routine (8%), problems in acquiring prescriptions (3%), and stress (7%). According to reports, many epilepsy clinics closed their doors during the pandemic. There was also a significant delay in imaging and intervention for epilepsy [107]. This led to vulnerable populations, including Black, Asian, and Minority Ethnic (BAME) groups, the elderly, and people from lower socioeconomic incomes, being more affected due to health service inequality [107].

Conclusions
COVID-19 has led to developing and worsening multiple neurological disorders, including stroke, Parkinson’s disease, multiple sclerosis, epilepsy, Alzheimer’s disease, and delirium. On the other hand, the pre-existing neurological conditions triggered increased severity during COVID-19, such as the increased requirement for ICU management, and those with pre-existing dementia led to the development of delirium. The medications used to treat pre-existing neurological disorders may play a significant role in developing complications. Furthermore, specific social barriers such as social isolation and difficulty acquiring medications may have triggered an increased frequency of epileptic episodes. In addition to the development and worsening of symptoms, it has also led to increased risk for hospitalization and mortality. We believe that this systematic review has shed important light on the relationship between neurological disorders and COVID-19. It will encourage medical personnel to take extra caution while managing neurological impairments, such as monitoring for stroke using ECMO, improving access to anti-epileptic medications, and considering the risk-benefit ratio of using disease-modifying drugs in multiple sclerosis. Further research is needed to understand this phenomenon, and this systematic review has significantly contributed to the existing literature.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Nazari S, Azari Jafari A, Mirmoeeni S, et al.: Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis. Brain Behav. 2021, 11:e02025. 10.1002/brb3.2025
2. Desforges M, Le Coupener A, Dubeau P, Bourguin A, Lajoie L, Dubé M, Talbot PJ: Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?. Viruses. 2019, 12:14. 10.3390/v12010014
3. Bartolome F, Rosa L, Valenti P, et al.: Lactoferrin as immune-enhancement strategy for SARS-CoV-2 infection in Alzheimer’s disease patients. Front Immunol. 2022, 13:878201. 10.3390/fimmu.2022.878201
4. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016/S0140-6736(20)30565-3
5. Helmich RC, Bloom BR: The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. I Parkinsons Dis. 2020, 10:551-4. 10.3233/PID-200038
6. Li Y, Li H, Fan R, et al.: Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children. Intervirology. 2016, 59:163-9. 10.1159/000450566
7. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021, 18:e1005583. 10.1371/journal.pmed.1005583
8. Azadi- Pooya AA, Emami A, Akbari A, Javanmardi F: COVID-19 presentations and outcome in patients with epilepsy. Acta Neurol Scand. 2021, 143:624-8. 10.1111/ane.13404
9. Brown EG, Chahine LM, Goldman SM, et al.: The effect of the COVID-19 pandemic on people with
Parkinson’s disease. J Parkinsons Dis. 2020, 10:1565-77. 10.3233/JPD-202249
10. Drabik L, Derbisz J, Chatrys-Bogacka Z, et al.: Neurological prognostic factors in hospitalized patients with COVID-19. Brain Sci. 2022, 12:193. 10.3390/brainsci12020193
11. El-Qushayri AE, Ghazy S, Reda A, Kamel AM, Abbas AS, Dmytriw AA: The impact of Parkinson’s disease on manifestations and outcomes of Covid-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2022, 32.e2278. 10.1002/rmv.2278
12. Eskandar EN, Altschul DJ, de la Garza Ramos R, et al.: Neurologic syndromes predict higher in-hospital mortality in COVID-19. Neurology. 2021, 96:e1527-38. 10.1212/WNL.0000000000011536
13. Fan M, Qiu W, Bu B, et al.: Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020, 7:e787. 10.1212/NXI.0000000000007087
14. Flores-Silva FD, Garcia-Grimshaw M, Valdes-Ferrer SI, et al.: Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City. PLoS One. 2021, 16:e0247455. 10.1371/journal.pone.0247455
15. Garjani A, Middleton RM, Nicholas R, Evangelou N: Recovery from COVID-19 in multiple sclerosis: a prospective and longitudinal cohort study of the United Kingdom multiple sclerosis register. Neurol Neuroimmunol Neuroinflamm. 2022, 9:e1118. 10.1212/NXI.0000000000011118
16. Harb AA, Chen R, Chase HS, Natajaran K, Noble JM: Clinical features and outcomes of patients with dementia compared to an aging cohort hospitalized during the initial New York City COVID-19 wave. J Alzheimers Dis. 2021, 81:679-90. 10.3233/JAD-210050
17. Hu Y, Yang H, Hou C, et al.: COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank. BMC Neuro. 2022, 22:15. 10.1186/s12883-021-02556-7
18. Huber MK, Raichele C, Lingor P, et al.: Outcomes of SARS-CoV-2 infections in patients with neurodegenerative diseases in the LEbSS cohort. Mov Disord. 2021, 36:791-9. 10.1002/mds.28554
19. Kubota T, Kuroda N: Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosci. 2021, 200:106549. 10.1016/j.cjnee.2020.106549
20. Kuroda N: Epilepsy and COVID-19: associations and important considerations. Epilepsy Behav. 2020, 108:107122. 10.1016/j.yebeh.2020.107122
21. Louaper C, Collongues N, Stankoff B, et al.: Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020, 77:1079-88. 10.1001/jamaneurol.2020.2581
22. Nejad JH, Allayahi F, Hosseinzadeh R, Heiat M, Ranjbar R: Neurological symptoms of COVID-19 infection; a cross-sectional study on hospitalized COVID-19 patients in Iran. Clin Neurol Neurosci. 2021, 210:106985. 10.1016/j.cjnee.2021.106985
23. Numbers K, Brodaty H: The effects of the COVID-19 pandemic on people with dementia . Nat Rev Neurol. 2021, 17:69-70. 10.1038/s41582-020-00450-9
24. Parrotta E, Kister I, Charvet L, et al.: COVID-19 outcomes in MS: Observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflamm. 2020, 7:e855. 10.1212/NXI.0000000000000885
25. Santos-Garcia D, Oreiro M, Pérez P, et al.: Impact of coronavirus disease 2019 pandemic on Parkinson’s disease: a cross-sectional survey of 568 Spanish patients. Mov Disord. 2020, 35:1712-6. 10.1002/mds.28261
26. Yassin A, Nawaish M, Shaban A, Alsherbini K, El-Salem K, Soudah O, Abu-Rub M: Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol. 2021, 21:1358. 10.1186/s12883-021-02161-4
27. Zhang L, Sun W, Wang Y, et al.: Clinical course and mortality of stroke patients with coronavirus disease 2019 in Wuhan, China. Stroke. 2020, 51:2647-82. 10.1161/STROKEAHA.120.035042
28. Filatov A, Sharma P, Hindi F, Espinosa PS: Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. 2020, 12:e7552. 10.7759/cureus.7552
29. Benassi A, Pilotto A, Premi E, et al.: Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020, 95:e910-20. 10.1212/25WNL.0000000000009948
30. Oxley TJ, Mocco J, Majidi S, et al.: Large-vessel stroke as a presenting feature of covid-19 in the young. N Engl J Med. 2020, 382:e60. 10.1056/NEJMoa2009787
31. Li Y, Li M, Wang M, et al.: Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020, 5:279-84. 10.1136/sov-2020-000451
32. Lee SG, Fralic M, Gholzinger M: Coagulopathy associated with COVID-19. CMAJ. 2020, 192:E583. 10.1503/cmaj.200685
33. Siepmann T, Sedghi A, Simon E, et al.: Increased risk of acute stroke among patients with severe COVID-19: a multicenter study and meta-analysis. Eur J Neurol. 2021, 28:238-47. 10.1111/ene.14555
34. Varga Z, Flammer AJ, Steiger P, et al.: Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395:1417-8. 10.1016/S0140-6736(20)30937-5
35. Carod-Artal FJ: Neurological complications of coronavirus COVID-19. Rev Neurol. 2020, 70:311-22. 10.3339/ren.2009.200179
36. Chavda V, Chaurasia B, Fiorindi A, Umana GE, Lu B, Montemurro N: Ischemic stroke and SARS-CoV-2 infection: the bidirectional pathology and risk morbidities. Neurol Int. 2022, 14:391-405. 10.3390/neurolint14020052
37. Ribas M, Biava G, Antinori A: HIV-associated venous thromboembolism. Medit J Hematol Infect Dis. 2011, 5:e2011030. 10.4084/MJHID.2011.030
38. Cho SM, Premraj L, Fanning J, et al.: Ischemic and hemorrhagic stroke among critically ill patients with coronavirus disease 2019: An international multicenter coronavirus disease 2019 critical care consortium study. Crit Care Med. 2021, 49:e1225-33. 10.1097/CCM.0000000000005209
39. Poyiadji N, Shuhin G, Noujaim D, Stone M, Patel S, Griffin B: COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020, 296:E119-20. 10.1148/radiol.202021187
40. Lapchak PA, Wu Q: Vascular dysfunction in brain hemorrhage: Translational pathways to developing new treatments from old targets. J Neurol Neurophysiol. 2011, 2011:51-e001. 10.4172/2155-9562.S1-e001
41. Morelli N, Rota E, Terracciano C, et al.: The baffling case of ischemic stroke disappearance from the casualty department in the COVID-19 era. Eur Neurol. 2020, 83:213-5. 10.1159/000507666
42. Dodd WS, Jabbour PM, Sweid A, et al.: Aneursymal subarachnoid hemorrhage in patients with coronavirus disease 2019 (COVID-19): a case series. World Neurosurg. 2021, 152:559-64. 10.1016/j.wneu.2021.06.092
43. Green HF, Khosoussi S, Sweenningson P: Plasma IL-6 and IL-17A correlate with severity of motor and non-motor symptoms in Parkinson’s disease. J Parkinsons Dis. 2019, 9:705-9. 10.3235/JPD-191699
44. Fasanero A, Antonioni A, Katzschschlager R, et al.: Management of advanced therapies in Parkinson’s disease patients in times of humanitarian crisis: the COVID-19 experience. Mov Disord Clin Pract. 2020, 7:361-72. 10.1002/mdc3.12963
45. Guo D, Han B, Lu Y, et al.: Influence of the COVID-19 pandemic on quality of life of patients with Parkinson’s disease. Parkinsons Dis. 2020, 2020:1216568. 10.1155/2020/1216560
46. Toljan K: Letter to the editor regarding the viewpoint "evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanism". ACS Chem Neurosci. 2020, 11:1192-4. 10.1021/acscchemneuro.0c00174
47. Idrees D, Kumar V: SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun. 2021, 554:94-8. 10.1016/j.bbrc.2021.03.100
48. Xia X, Jiang Q, McDermott J, Han JF: Aging and Alzheimer’s disease: comparison and associations from molecular to system level. Aging Cell. 2018, 17:e12802. 10.1111/ace.12802
49. Lee S, Vigar F, Zimmerman ME, et al.: White matter hyperintensities are a core feature of Alzheimer’s disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016, 79:929-39. 10.1002/ana.24647
50. Wen Y, Yang S, Liu R, Simpkins JW: Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res. 2004, 1022:30-8. 10.1016/j.brainres.2004.05.016
51. Papad E, Rejdak K: The role of myelin damage in Alzheimer’s disease pathology. Arch Med Sci. 2020, 16:545-51. 10.5114/ams.2018.76665
52. Lahiri S, Regis GC, Koronyo Y, et al.: Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer’s disease mice. Crit Care. 2019, 25:63. 10.1186/s13054-019-2536-2
53. van Langelaar J, Riveris L, Smolders J, van Luijn MM: B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol. 2020, 11:760. 10.3389/fimmu.2020.00760
54. Liu J, Li S, Liu J, et al.: Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020, 55:102763. 10.1016/j.ebiom.2020.102763
55. Qiu ZF, Li TS, Fan HW, Han Y, Xie J, Wang AX, Deng GH: Dynamics of T lymphocyte subsets in SARS patients (Article in Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003, 25:525-8.
56. Bucaraciu MC, Fornasiero A, Romano S, et al.: The contribution of gut barrier changes to multiple sclerosis pathophysiology. Front Immunol. 2019, 10:1916. 10.3389/fimmu.2019.01916
57. Razi G, Taribblan B, Teixeira AM, et al.: Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise. Mult Scler Relat Disord. 2022, 59:105357. 10.1016/j.msard.2022.105357
58. Dubé M, Le Coupacne A, Wong AH, Rini JM, Desforges M, Talbot PJ: Aortal stress enables neuron-to-neuron propagation of human coronavirus OC43. J Virol. 2018, 92:e00404-18. 10.1128/JVI.00404-18
59. Mekkawy DA, Hamdy S, Abdel-Naseer M, et al.: Neurological manifestations in a cohort of Egyptian patients with COVID-19: a prospective, multicenter, observational study. Brain Sci. 2022, 12:74. 10.3390/brainsci12070076
60. Rocha-Filho PAS, Magalhães JE, Silva DF, Soares MC, Buarque LMA, Gama MDP, Oliveira FA: Neurological manifestations as prognostic factors in COVID-19: a retrospective cohort study. Acta Neurol Belg. 2022, 122:725-33. 10.1007/s13760-021-01851-7
61. Trifan G, Goldenberg FD, Caprio FZ, et al.: Characteristics of a diverse cohort of stroke patients with SARS-CoV-2 and outcome by sex. J Stroke Cerebrovasc Dis. 2020, 29:105314. 10.1016/j.jstrokecerebrovasdis.2020.105314
62. Bekelis K, Missios S, Ahmad J, et al.: Ischemic stroke occurs less frequently in patients with COVID-19: a multicenter cross-sectional study. Stroke. 2020, 51:3570-6. 10.1161/STROKEAHA.120.031217
63. Avula A, Nalleballe K, Narula N, et al.: COVID-19 presenting as stroke. Brain. Immunol. 2020, 87:115-9. 10.1016/j.brainimmun.2020.04.077
64. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-20. 10.1056/NEJMoa2002032
65. Qin C, Zhou L, Hu Z, et al.: Clinical characteristics and outcomes of COVID-19 patients with a history of stroke in Wuhan, China. Stroke. 2020, 51:2219-23. 10.1161/STROKEAHA.120.030565
66. Li S, Ren J, Hou H, et al.: The association between stroke and COVID-19-related mortality: a systematic review and meta-analysis based on adjusted effect estimates. Neurol Sci. 2022, 43:4049-59. 10.1007/s10072-022-06024-9
67. Divani AA, Andalib S, Di Napoli M, et al.: Coronavirus disease 2019 and stroke: Clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis. 2020, 29:104941. 10.1016/j.jstrokecerebrovasdis.2020.104941
68. Yang X, Hu M, Yu Y, et al.: Extracerebral membrane oxygenation for SARS-CoV-2 acute respiratory distress syndrome: a retrospective study from hubei, China. Front Med (Lausanne). 2020, 7:11460. 10.3390/med.711460
69. Sutter R, Trispal K, Marsch S: Acute neurologic complications during extracerebral membrane oxygenation: a systematic review. Crit Care Med. 2018, 46:1506-13. 10.1097/CCM.0000000000005722
70. Robinson CP, Buss KM: Severe COVID-19 and stroke-another piece in the puzzle. Crit Care Med. 2021, 49:2160-8. 10.1097/CCM.0000000000005225
71. Spence ID, de Freitas GR, Pettigrew LC, et al.: Mechanisms of stroke in COVID-19. Cerebrovasc Dis. 2020, 49:451-8. 10.1055/s-0030-1259831
72. Purrucker JC, Haas K, Rixoz T, et al.: Early clinical and radiological course, management, and outcome of
intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016, 73:169-77. 10.1001/jamaneurol.2015.5682

73. Dogra S, Jain R, Caso M, et al.: Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis. 2020, 29:104984. 10.1016/j.jstrokecerebrovasdis.2020.104984

74. Dybdah D, Walliger G, Pershing M, Collins C, Robinson D: Enoxaparin dosing for venous thromboembolism prophylaxis in low body weight patients. Clin Med Insights Blood Disord. 2019, 12:1179545X19865814. 10.1177/1179545X19865814

75. Fatehi P, Hesam-Shariati N, Abouzari Jamour P, Fathi F, Shariati MBH: Acute ischemic and hemorrhagic stroke and COVID-19: case series. SN Compr Clin Med. 2020, 2:2596-401. 10.1016/s42539-020-00059-8

76. Escalad S, Maier B, Redjim H, et al.: Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke. 2020, 51:3540-53. 10.1161/STROKEAHA.120.030754

77. Ladopoulos T, Zard R, Shahjouloue S, et al.: COVID-19: Neuroimaging features of a pandemic. J Neuroimaging. 2021, 51:228-45. 10.1111/jon.12819

78. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020, 18:1094-9. 10.1111/jth.14817

79. Asakura H, Ogawa H: Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020, 18:1521-2. 10.1111/jth.14858

80. Wang L, Zhang Y, Zhang S: Cardiovascular impairment in COVID-19: Learning from current options for cardiovascular anti-inflammatory therapy. Front Cardiovasc Med. 2020, 7:78. 10.3389/fcmv.2020.00078

81. Zhang W, Zhao Y, Zhang F, et al.: The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020, 214:108395. 10.1016/j.clim.2020.108395

82. Beigel JH, Tomashek KM, Dodd LE, et al.: Remdesivir for the treatment of covid-19: a final report. N Engl J Med. 2020, 383:1813-26. 10.1056/NEJMoa2007764

83. Tan YK, Goh C, Leow AS, et al.: COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020, 50:587-95. 10.1007/s11239-020-02228-y

84. Petirillo S, Schirinzì T, Di Lazzaro G, et al.: Systemic activation of Nrf2 pathway in Parkinson's disease. Mov Disord. 2020, 35:180-4. 10.1002/mds.27878

85. Li WS, Chan LL, Chao YX, Tan EK: Parkinson’s disease following COVID-19: causal link or chance occurrence?. J Transl Med. 2020, 18:493. 10.1186/s12967-020-02670-9

86. Bousali-Benazzouz R, Benazzouz A: Covid-19 infection and parkinsonism: is there a link?. Mov Disord. 2021, 36:1737-45. 10.1002/mds.28680

87. Sulzer D, Antonini A, Leta V, et al.: COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020, 6:18. 10.1038/s41531-020-00123-0

88. Putri C, Hariyanto TL, Hananto RE, Christian K, Situmeang RF, Kurniawan A: Outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021, 87:155-61. 10.1016/j.parkreldis.2021.04.019

89. Ciaccio M, Lo Sasso B, Scacchette C, et al.: COVID-19 and Alzheimer’s disease. Brain Sci. 2021, 11:305. 10.3390/brainsci11030305

90. Antonini A, Leta V, Teo J, Chaufturri KR: Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord. 2020, 35:905-8. 10.1002/mds.28104

91. Bianchetti A, Rozzini R, Guerini F, et al.: Clinical presentation of COVID-19 in dementia patients. J Nutr Health Aging. 2020, 24:560-2. 10.1007/s11357-020-00207-y

92. Poloni TE, Carlos AF, Cairati M, et al.: Prevalence and prognostic value of delirium as the initial presentation of COVID-19 in the elderly with dementia: an Italian retrospective study. EClinicalMedicine. 2020, 26:100490. 10.1016/j.eciim.2020.100490

93. Tincioni A, Cerundolo N, Parise A, et al.: Delirium in COVID-19: epidemiology and clinical correlations in a large group of patients admitted to an academic hospital. Aging Clin Exp Res. 2020, 32:1519-66. 10.1007/s40520-020-00169-6

94. Hascupp ER, Hascupp KN: Does SARS-CoV-2 infection cause chronic neurological complications?. Geroscience. 2020, 42:1083-7. 10.1007/s11357-020-00207-y

95. Park M, Cook AR, Lim JT, Sun Y, Dickens BL: A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med. 2020, 9:967. 10.3390/jcm9090967

96. Coolen T, Lollis V, Sadeghi N, et al.: Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 2020, 95:e2616-27. 10.1212/wnl.000000000010116

97. Virhammar J, Nääs A, Fällmar D, et al.: Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2021, 28:3324-31. 10.1111/ene.14705

98. Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH: Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am J Geriatr Psychiatry. 2020, 28:712-21. 10.1016/j.jagp.2020.04.010

99. Filippi M, Brück W, Chard D, et al.: Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019, 18:198-210. 10.1016/S1474-4422(18)30451-4

100. Sudre CH, Murray B, Varsavsky T, et al.: Attributes and predictors of long COVID. Nat Med. 2021, 27:626-31. 10.1038/s41591-021-01292-y

101. Saltie A, Fox RJ, Newsome SD, et al.: Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021, 78:699-708. 10.1001/jama.neurol.2021.0608

102. Thompson EJ, Williams DM, Walker AJ, et al.: Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. MedRxiv. 2021, 10.1101/2021.06.24.21259277

103. Živković SA, Gruner G, Narayanaswami P: Doctor-should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders. Muscle Nerve. 2021, 63:294-303.
104. Marsh EB, Kornberg M, Kessler K, et al.: COVID-19 and vaccination in the setting of neurologic disease: an emerging issue in neurology. Neurology. 2021, 97:720-8. 10.1212/WNL.0000000000012578

105. Vogrig A, Gigli GL, Bnà C, Morassi M.: Stroke in patients with COVID-19: Clinical and neuroimaging characteristics. Neurosci Lett. 2021, 743:135564. 10.1016/j.neulet.2020.135564

106. Amruta N, Chastain WH, Paz M, et al.: SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev. 2021, 58:1-15. 10.1016/j.cytogfr.2021.02.002

107. Thorpe J, Ashby S, Hallab A, et al.: Evaluating risk to people with epilepsy during the COVID-19 pandemic: preliminary findings from the COV-E study. Epilepsy Behav. 2021, 115:107658. 10.1016/j.yebeh.2020.107658

108. Fonseca E, Quintana M, Lallana S, et al.: Epilepsy in time of COVID-19: a survey-based study. Acta Neurol Scand. 2020, 142:545-54. 10.1111/ane.13335